Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Among all the awards and mementos Moderna ...
Hace ya varios meses que los vecinos de Bailén sufren malos olores y que afectan a distintas zonas de la localidad jiennense. Una sensación que se intensifica aún más por las altas temperaturas ...
Moderna has touted the potential of its ever-expanding mRNA platform, which includes an in vivo candidate, during its annual Science Day. Held on 25 June, Moderna told participants that it will ...
At its latest R&D update, Moderna revealed a move into the pioneering in vivo CAR-T category, adding another treatment class to its R&D capabilities. It has nominated a lead candidate in the in vivo ...
Moderna has unveiled its first in vivo CAR-T program. Building on other groups’ ex vivo CAR-T data, the company plans to start clinical development of an off-the-shelf autoimmune disease prospect, ...
Moderna Inc. Chief Executive Officer Stephane Bancel said he sees the pending launch of a planned flu vaccine as a chance to start a public conversation about how mRNA technology can offer better ...
NEW YORK – Moderna's next endeavor is an in vivo CAR T-cell therapy for autoimmune diseases, which it plans to take into the clinic in 2027. The company will begin testing mRNA-6007, which executives ...
In a sudden reversal of fortune, Moderna stock snapped a six-day winning streak on Monday to become one of the worst-performing stocks in the S&P 500.
The FDA’s independent vaccine advisors voted unanimously 9-0 that the benefits outweigh the risks for Moderna’s mFlusiva shot in people ages 50 to 64 as well as 65 and older. The shot is the first of ...
A first-of-its-kind flu shot is one step closer to being available to the public after a Food and Drug Administration (FDA) advisory panel voted Thursday to recommend Moderna’s mRNA-based vaccine for ...
A federal vaccine advisory panel today gave its stamp of approval to Moderna’s mRNA influenza vaccine (mRNA-1010) for older adults. By a unanimous vote, the Food and Drug Administration’s (FDA’s) ...
WASHINGTON (AP) — A new kind of flu vaccine moved a step closer to the U.S. market Thursday as federal health advisers recommended approval of the first made with the same mRNA technology that was key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results